司 研 究 永艺股份（603600.SH） 全球化布局韧性凸显，下半年需求回暖可期 投资要点： 公 司 财 公司发布 2025 年半年度报告。25H1 公司实现营收 21.89 亿元，同比 +6.66%，归母净利润 1.33 亿元，同比+4.92%，扣非归母净利润 1.29 亿元， 同比+2.74%。单季度看，25Q2 实现营收 11.78 亿元，同比-1.42%，归母净 利润 0.75 亿元，同比-10.34%，扣非归母 0.75 亿元，同比-9.36%。Q2 同比 下滑主要受行业对美出口疲软及同期高基数影响。 报 点 评 全球化布局成效凸显，大客户战略持续深化。分区域来看，25H1 公司 外销/内销营收分别为 16.42/5.41 亿元，同比分别增长 3.7%/15.4%。受新一 轮关税战影响，美国市场家具类产品终端需求走弱，叠加关税政策不确定 性使渠道商采购备库更加谨慎，同时订单加快从中国向外转移，中国办公 椅出口额同比-7.22%，其中对美国的出口额同比-29.37%。面对贸易摩擦与 产能结构性转移，公司大客户战略与前瞻性的全球化产能布局构筑了坚实 的护城河，一方面，公司始终坚持"数一数二"市场战略， ...

Core Viewpoint - The company is enhancing its strategic focus on major clients by establishing a dedicated service team to improve customer response efficiency and satisfaction, while expanding its collaboration with multinational corporations (MNCs) across the entire drug development cycle [1] Group 1: Strategic Initiatives - The company has initiated a major client strategy since last year, forming a "triangular" business team consisting of client managers, solution managers, and delivery managers to provide in-depth services to strategic clients [1] - A specialized major client service team has been established this year to coordinate business development resources across regions including China, the US, and Europe, significantly improving customer response efficiency and satisfaction [1] Group 2: Collaboration with MNCs - The collaboration with MNCs has evolved from supplying molecular building blocks to a comprehensive CMC (Chemistry, Manufacturing, and Controls) service, with increasing depth and project scale [1] - The company now covers the entire R&D cycle for MNCs, including drug discovery, clinical development, and CMC services from clinical phases I-III to commercialization [1] Group 3: Innovation and Project Development - The company is leveraging its solid foundation of cooperation and client trust to enter the new molecular pipeline development field for MNCs, with ongoing projects in cutting-edge areas such as peptides (non-natural amino acid building blocks) and ADC (antibody-drug conjugates) design [1] - The company is continuously deepening its collaborative efforts in innovative therapies [1]

Group 1: Company Strategy and Development - The company implements a "2+X" strategy focusing on innovative pharmaceuticals and agricultural chemicals CDMO business, establishing stable partnerships with leading global companies [2] - The production system is structured around "six cores + two collaborations," enhancing the R&D process from laboratory to commercial production [2][3] - The company aims to create a comprehensive "R&D-production" lifecycle chain to support high-end innovative products [2] Group 2: Agricultural Chemicals Business - The company has established a production capacity of 2,000 tons/year for chlorantraniliprole intermediates at the Nantong base, serving international agricultural clients for over a decade [3] - The Yancheng base has a production line for custom pesticide projects with an annual capacity of 500 tons, expected to start supplying next year [15] - The Lanzhou base has achieved a production capacity of approximately 500 tons/year for innovative pesticide intermediates, with an additional 1,000 tons/year capacity under installation [15] Group 3: Pharmaceutical Business - The company has over 20 years of experience in the pharmaceutical CDMO sector, providing comprehensive solutions from early drug development to commercial production [12] - The Taicang base has a production capacity of 60 tons/year for the raw material Levetiracetam, while the Malta base supports over 20 types of pharmaceutical raw materials [9] - The Lanzhou pilot base has established a production line for antiviral drug intermediates with an annual capacity of 15 tons [9] Group 4: Strategic Partnerships - The collaboration with Heng Rui Medicine exemplifies the company's "big client strategy," focusing on innovative product commercialization [12] - Plans for 2025 include launching 5-10 cooperative products, with at least 10 products planned for 2026 [11] - The partnership has expanded from small-scale experiments to comprehensive strategic cooperation across multiple therapeutic areas [12] Group 5: Future Outlook and Investment - The company is preparing to invest in new projects and expand production capacity, with over 100 acres of land reserved for future pharmaceutical and agricultural projects [9] - The company anticipates a gradual recovery in agricultural business performance as new projects are implemented [16] - Continuous investment in core technologies and service capabilities is expected to drive high-quality development in the pharmaceutical sector [12]

Group 1: Company Overview and Strategy - The company is currently in the process of renewing its cooperation agreement with FMC, with ongoing discussions on relevant terms [1] - The company is implementing a "big customer strategy," transitioning to a diversified model with several core enterprise customers and multiple key innovative products [1][2] - The company has established long-term partnerships with leading pesticide companies, indicating a high entry barrier in the CDMO business [3] Group 2: Financial Performance and Challenges - The company reported a loss of 258 million yuan in 2024, primarily due to a goodwill impairment of 106 million yuan and a cyclical downturn in the pesticide industry [5] - The company’s short-term loans increased by 42.7%, with a debt ratio of 46.11%, but it maintains a strong repayment capability and has never defaulted [9] Group 3: Business Development and Future Plans - The company has a clear strategic plan for its pharmaceutical business, focusing on expanding GMP-compliant production capacity and maintaining a "big customer strategy" [7] - The Yancheng base is operational, with the second phase ready for use, expected to positively contribute to the pesticide business [8] - The company is cautiously expanding its health business, leveraging its synthetic biology and chemical synthesis technology platforms [10] Group 4: Research and Development - The company emphasizes a technology-driven development strategy, maintaining high R&D investment despite recent performance challenges [12] - The company aims to enhance its core competitiveness and build a solid technological barrier through continuous product development [12] Group 5: Shareholder Relations and Market Management - The company has not declared dividends for 2024 but maintains a positive attitude towards future dividend policies [13] - The company has implemented a market value management plan to enhance its business foundation and maintain investor relations [14]

Group 1: Company Performance and Financials - The company's pharmaceutical production line has a low capacity utilization rate due to the inclusion of historical cooperative production orders in the reported capacity, leading to a discrepancy between reported and actual utilization rates. However, the actual utilization is at a good level, with stable revenue and profit from the pharmaceutical sector [1] - In Q1 2025, the company experienced significant improvement in operations, with the agricultural protection sector stabilizing its gross margin and the pharmaceutical sector developing steadily. This was aided by an increase in foreign exchange gains and a turnaround from losses to profits in foreign exchange hedging derivatives, resulting in a notable increase in net profit [1] - The company anticipates a breakthrough in revenue from its new energy business in 2025, despite facing pressure from intense market competition and depreciation costs from fixed assets [1] Group 2: Business Development and Strategy - The pharmaceutical business is expected to grow in 2025, focusing on "key customers," primarily leading global pharmaceutical companies based in Europe. The company is enhancing existing partnerships while developing new clients and strengthening R&D capabilities [2] - The company is actively communicating with clients and developing projects in the new energy sector, with plans to introduce products like electrolytes and additives to the market [4] - The UK and Malaysia factories are part of a strategy to provide stable supply chains and comprehensive product delivery capabilities. The UK factory is expected to see improved capacity utilization and profitability in 2025, while the Malaysia factory is still in the construction phase [5][6] Group 3: R&D and Product Development - The development cycle for new agricultural protection products is generally shorter than that for pharmaceutical products, with the company providing kilogram-scale samples after clients complete molecular efficacy validation [3] - The company has invested significantly in R&D across agricultural protection, pharmaceuticals, and functional chemicals, achieving partial commercialization of products and production lines in 2024. Future R&D efforts will focus on optimizing existing products and extending advantageous technologies based on client needs [6]

Core Insights - Company achieved record revenue in Q1 2025, driven by a decade-long strategy of targeting major clients, continuous technological innovation, and responsiveness to global market changes [1][9][12] Group 1: Company Performance - In Q1 2025, the company reported revenue of 5.55 billion yuan and a net profit of 460 million yuan, marking a year-on-year growth of 12.47% [9][12] - For the full year 2024, the company achieved revenue of 24.03 billion yuan, a 20.12% increase, and a net profit of 1.94 billion yuan, up 174.19% [9][12] - The average selling price of products increased by approximately 9.43% in Q1 2025, with a gross margin of 26.81% [12] Group 2: Market Position and Industry Dynamics - The global polyurethane market is projected to grow from 81.4 billion USD in 2024 to 112 billion USD by 2029, indicating strong demand for high-performance materials [4] - The polyurethane industry in China has low market concentration, with the top four companies holding only 19.3% of the market share, leading to intense competition [8] - The company has positioned itself as a leader in the polyurethane composite materials sector, leveraging technological innovation to develop differentiated products [8][9] Group 3: Client Relationships and Strategic Partnerships - The company has successfully established partnerships with major global brands such as Nike, Adidas, and Apple, enhancing its market presence [16][18] - After a decade of effort, the company became a strategic partner of Nike, which significantly boosted its market access and credibility [16][18] - The company’s sales to the U.S. market represent only 2.55% of total revenue, indicating limited exposure to potential tariff impacts [20][22] Group 4: Technological Innovation - The company has focused on developing high-performance, multifunctional, and eco-friendly products, which has allowed it to maintain a competitive edge [8][9] - Recent advancements include the introduction of over 30 new materials, such as water-based and solvent-free products, which have increased their market appeal [9][12]

Group 1: Market Performance - The overseas market experienced a year-on-year growth of 19.88% in 2024, achieving a revenue of 518 million [1] - The company has 16 years of experience in overseas market expansion, covering over 100 countries and regions [1] - The demand for digital equipment in the denture processing industry is slowing down in China, the US, and Europe, while the chairside market still holds significant potential [2] Group 2: Product Development and Sales - The company completed the acquisition of Korean Wolan in May 2024, with expected revenue of over 18 million in the second half of 2024 [2] - The narrow-neck implant and digital surgical tool kit from Wolan are expected to receive NMPA certification this year, with the ALL-ON-X occlusion reconstruction plan set to launch soon [3] - Sales of zirconia products are maintaining a medium to high growth rate, with stable prices and improved gross margins [6] Group 3: International Strategy and Risk Management - The European market accounts for the highest share of overseas revenue, followed by the Americas, with notable growth in the Middle East and Asia [4] - The US tariff policy has a controllable impact on the company's exports, with 38.15% of revenue coming from the domestic market, providing growth space and policy support [4] - The company plans to increase inventory at its US subsidiary to mitigate short-term impacts from tariffs [5] Group 4: Client Strategy and Market Expansion - In 2024, the company achieved significant results in large client cooperation, increasing the procurement budget share from major clients [6] - The company aims to build a global ecosystem of large and quality clients, promoting industry progress [6] - The company is enhancing brand building for Wolan and providing diverse training courses to strengthen market promotion [3] Group 5: Future Growth and Value Creation - The company expects stable growth in overseas business due to product quality, technological innovation, and customer service advantages [8] - The company focuses on core business development and technological innovation to enhance market competitiveness and profitability [9] - A stable cash dividend policy and improved investor relations management are part of the company's value realization strategy [9]

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Views - The company achieved a revenue of 695 million yuan in 2024, representing a year-on-year growth of 48.3%, and a net profit of 45 million yuan, up 10.3% year-on-year, which met expectations [7] - The company plans to distribute a cash dividend of 3.0 yuan per share (including tax) for 2024, with a distribution ratio of 56.71% [7] - In Q1 2025, the company reported a revenue of 162 million yuan, a year-on-year increase of 40.1%, and a net profit of 9 million yuan, up 8.8% year-on-year, slightly below expectations [7] - The company is focusing on a major client strategy and has formed partnerships with emerging brands to drive revenue growth, with domestic revenue reaching 642 million yuan in 2024, a 40.5% increase [7] - The company is enhancing its raw material research and investment to improve integrated capabilities and increase the value-added of its OEM services [7] - The profit forecast for 2025-2027 has been adjusted downwards, with expected net profits of 69 million yuan, 91 million yuan, and 115 million yuan respectively [7] Financial Data and Profit Forecast - Total revenue is projected to reach 1,009 million yuan in 2025, with a year-on-year growth rate of 45.2% [6] - The gross profit margin is expected to be 26.4% in 2025, with a net profit margin of 6.5% [6] - The company’s return on equity (ROE) is forecasted to be 15.6% in 2025 [6] - The earnings per share (EPS) is projected to be 0.81 yuan in 2025 [6]

Investment Rating - The report does not explicitly provide an investment rating for the agricultural chemicals and veterinary drugs industry [1]. Core Insights - The agricultural chemicals industry is nearing the end of a "de-inventory" phase, with signs of order volume recovery observed in Q4 2024. The company plans to maintain its "major client strategy" while expanding its customer base and exploring new product directions [18]. - The pharmaceutical business is progressing as planned, with stable development expected. The company is focusing on deepening relationships with existing major clients and enhancing R&D capabilities [19]. - The renewable energy business is advancing, with plans to enter the market with products like electrolytes. The company aims for revenue breakthroughs in 2025 while optimizing technology and operational efficiency to remain competitive [20]. - The establishment of operations in the UK and Malaysia is intended to provide a stable supply chain and enhance service quality for clients, countering trends of industry chain relocation [20]. - The impact of U.S. tariff policies on the company's business is limited, as the share of products delivered to U.S. ports is small [20]. - The rise of Indian CDMO companies is acknowledged, but the company believes that its competitive edge in proprietary drugs remains intact due to concerns over supply chain integrity and IP protection in India [21]. Summary by Sections 1. Basic Research Information - The research focused on the company "Lianhua Technology" within the agricultural chemicals and veterinary drugs industry, conducted on March 12, 2025, with participation from various financial institutions [13]. 2. Detailed Research Institutions - The research involved institutions such as Kaiyuan Securities, Tianfeng Securities, Haitong Asset Management, and Industrial Bank [14]. 3. Research Institution Proportions - The report does not provide specific data on the proportions of research institutions involved [16]. 4. Main Content Information - The company is actively managing its inventory levels in the agricultural sector and is optimistic about future order volumes. It is also expanding its pharmaceutical and renewable energy businesses while maintaining a focus on major clients and operational efficiency [18][19][20].